

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: <http://www.elsevier.com/locate/crvasa>

## Guidelines

## 2016 ESC/EAS Guidelines for the management of dyslipidaemias

### Summary of the document prepared by the Czech Society of Cardiology<sup>☆</sup>

Petr Janský<sup>a,\*</sup>, Hana Rosolová<sup>b</sup>, Michal Vrablík<sup>c</sup><sup>a</sup>Department of Cardiovascular Surgery, University Hospital Motol, Prague, Czech Republic<sup>b</sup>Department of Internal Medicine II, University Hospital, Plzen, Czech Republic<sup>c</sup>Department of Internal Medicine III, General University Hospital, Prague, Czech Republic

**Authors of the original ESC/EAS full text document [1]: Alberico L. Catapano, Ian Graham, on behalf of The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).**

## ARTICLE INFO

## Article history:

Received 5 March 2017

Accepted 8 March 2017

Available online xxx

## Keywords:

Guidelines

Dyslipidaemias

Cholesterol

Triglycerides

Low-density lipoproteins

High-density lipoproteins

Apolipoprotein B

Lipoprotein remnants

Total cardiovascular risk

Treatment, lifestyle

Treatment, drugs

Treatment, adherence



ČESKÁ KARDIOLOGICKÁ SPOLEČNOST  
THE CZECH SOCIETY OF CARDIOLOGY

<sup>☆</sup> For permissions: please e-mail: [guidelines@escardio.org](mailto:guidelines@escardio.org).

\* Corresponding author.

E-mail address: [petr.jansky@razdva.cz](mailto:petr.jansky@razdva.cz) (P. Janský).

<http://dx.doi.org/10.1016/j.crvasa.2017.03.007>

0010-8650/© 2017 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.

## Contents

1. Preamble . . . . .	000
2. What is cardiovascular disease prevention? . . . . .	000
2.1. Definition and rationale . . . . .	000
2.2. Cost-effectiveness of prevention . . . . .	000
3. Total cardiovascular risk. . . . .	000
3.1. Total cardiovascular risk estimation . . . . .	000
3.2. Risk levels . . . . .	000
4. Evaluation of laboratory lipid and apolipoprotein parameters . . . . .	000
4.1. Fasting or non-fasting? . . . . .	000
4.2. Lipid and lipoprotein analyses . . . . .	000
5. Treatment targets . . . . .	000
6. Lifestyle modifications to improve the plasma lipid profile . . . . .	000
6.1. The influence of lifestyle on total cholesterol and low-density lipoprotein cholesterol levels . . . . .	000
6.2. Lifestyle recommendations to improve the plasma lipid profile . . . . .	000
6.3. Dietary supplements and functional foods for the treatment of dyslipidaemias . . . . .	000
6.4. Other features of a healthy diet contributing to cardiovascular disease prevention . . . . .	000
7. Drugs for treatment of hypercholesterolaemia . . . . .	000
7.1. Statins . . . . .	000
7.2. Bile acid sequestrants . . . . .	000
7.3. Cholesterol absorption inhibitors . . . . .	000
7.4. PCSK9 inhibitors . . . . .	000
7.5. Nicotinic acid . . . . .	000
8. Triglycerides and cardiovascular disease risk . . . . .	000
8.1. Strategies to control plasma triglycerides . . . . .	000
9. High-density lipoprotein cholesterol and cardiovascular risk. . . . .	000
10. Management of dyslipidaemia in different clinical settings . . . . .	000
10.1. Familial dyslipidaemias . . . . .	000
10.2. Children . . . . .	000
10.3. Women . . . . .	000
10.4. Older persons . . . . .	000
10.5. Diabetes and metabolic syndrome . . . . .	000
10.6. Patients with acute coronary syndrome and patients undergoing percutaneous coronary intervention . . . . .	000
10.7. Heart failure and valvular diseases . . . . .	000
10.8. Autoimmune diseases . . . . .	000
10.9. Chronic kidney disease . . . . .	000
10.10. Transplantation . . . . .	000
10.11. Peripheral arterial disease . . . . .	000
10.12. Stroke . . . . .	000
10.13. Human immunodeficiency virus patients . . . . .	000
10.14. Mental disorders . . . . .	000
11. Monitoring of lipids and enzymes in patients on lipid-lowering therapy . . . . .	000
12. Strategies to encourage adoption of healthy lifestyle changes and adherence to lipid-modifying therapies . . . . .	000
12.1. Achieving and adhering to healthy lifestyle changes . . . . .	000
12.2. Adhering to medications . . . . .	000
13. To do and not to do messages from the Guidelines . . . . .	000
References . . . . .	000

## 1. Preamble

### Development of the Joint Task Force guidelines

The present guidelines represent an evidence-based consensus of the European Task Force including the [European](#)

[Society of Cardiology \(ESC\) and the European Atherosclerosis Society \(EAS\)](#). The Task Force followed the quality criteria for development of guidelines, which can be found at <http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines>.

Download English Version:

<https://daneshyari.com/en/article/5577784>

Download Persian Version:

<https://daneshyari.com/article/5577784>

[Daneshyari.com](https://daneshyari.com)